MoFo Life Sciences

October 01, 2020 - AI + Robotics, United States, Intellectual Property
Special Patents and AI with Janet Xiao and Anna Yuan
By: Janet Xiao, Anna Yuan and Michael R. Ward
In this third installment of a six-part Patent Law Course offered by Morrison & Foerster and GSAS Harvard Biotech Club , MoFo partner and head of the firm’s China Life Sciences Group Janet Xiao taught a class on the value, protection, and legal issues involved
... ›
May 12, 2020 - AI + Robotics, United States, Intellectual Property
The USPTO Says No to Naming AI as a Patent Inventor
By: Anna Yuan and Karen G Potter
The increase in AI-related patent filings in the past few years has given rise to unique questions about the current patent system. In particular, the question of whether an AI system can or should be named as an inventor on a patent application has
... ›
March 12, 2020 - AI + Robotics, Global, Corporate + Venture Capital, Blockchain
The New ABC's: Artificial Intelligence, Blockchain and How Each Compliments the Other
By: Vivian L. Hanson and Lee Adam Nisson
Artificial intelligence (AI) and blockchain technology are two novel innovations that offer the opportunity for us to move beyond our legacy systems and streamline enterprise management and compliance in ways previously unimaginable. Each technology augments the strengths and tempers the weaknesses of the other.
... ›
March 05, 2020 - AI + Robotics, United States, FDA
February FDA Updates
As we move into 2020, we’re starting a regular blog series highlighting noteworthy FDA updates regarding regulatory compliance, fraud and abuse cases, and product development issues every month. Our February recap is below. 1. Two Owners of Telemedicine Companies Charged for Roles in $56
... ›
February 13, 2020 - AI + Robotics, European Union, Intellectual Property
CAN AI BE AN INVENTOR? NOT AT THE EUROPEAN PATENT OFFICE
By: Alistair Maughan and Anna Yuan
The European Patent Office has denied two patent applications on the grounds that an AI system cannot be listed as the inventor. For the first time, the European Patent Office (EPO) has issued a ruling on its approach to patent applications that designate artificial
... ›
January 21, 2020 - AI + Robotics, United States, FDA, Medical Devices + Diagnostics, Healthcare
Digital Health in 2019
The year 2019 saw relatively few developments in the digital health space. Although progress has been slow, FDA did make headway on two initiatives: (1) addressing the unique challenges of regulating artificial intelligence and machine learning (AI/ML) in medical applications, and (2) implementing changes
... ›
December 19, 2019 - AI + Robotics, Global, Data Analytics, Intellectual Property
Global IP Policy in the Age of AI
By: Karen G Potter
Between 2013 and 2016, the number of Artificial Intelligence (AI) related patent applications in the life sciences and medical sciences grew by about 40% * , and, with continuing advances in technology, has likely increased substantially since 2016. Although this finding may not come
... ›
October 30, 2019 - AI + Robotics, Medical Devices + Diagnostics, Data Analytics, Asia
Reflecting on the Challenges and Opportunities of Data at the Hitachi Social Innovation Forum 2019
Are companies keeping up with technological advances, and what are they doing specifically to contribute to society and provide value? What are the future prospects, and what kind of opportunities are being created for progress, including in the digital and scientific arenas? As Japanese
... ›
September 19, 2019 - AI + Robotics, United States, FDA, Product Liability + Class Action, Pharma, Regulatory, Data Analytics
Artificial Intelligence and Pharma
Bethany Hills authored an article for PHARMAnetwork , covering how the pharmaceutical industry has been adopting artificial intelligence and machine learning. Bethany discusses that the pharmaceutical sector has been one of the more robust areas where private partnerships with artificial intelligence-based technology companies have
... ›
August 28, 2019 - AI + Robotics, United States, Regulatory, Data Analytics, Intellectual Property
AI Patent Policy – Calling all Life Sciences Practitioners
By: Anna Yuan and Karen G Potter
In the life sciences, artificial intelligence (AI) may be facilitating a sea change in how diseases are diagnosed, prognosed, and treated, and even how therapies are discovered and produced. Indeed, it is possible for AI to provide insights into disease and treatment that could
... ›

Topic Archives: AI + Robotics

Special Patents and AI with Janet Xiao and Anna Yuan

By: Janet Xiao, Anna Yuan and Michael R. Ward

The USPTO Says No to Naming AI as a Patent Inventor

By: Anna Yuan and Karen G Potter

The New ABC's: Artificial Intelligence, Blockchain and How Each Compliments the Other

By: Vivian L. Hanson and Lee Adam Nisson

February FDA Updates

CAN AI BE AN INVENTOR? NOT AT THE EUROPEAN PATENT OFFICE

By: Alistair Maughan and Anna Yuan

Digital Health in 2019

Global IP Policy in the Age of AI

By: Karen G Potter

Reflecting on the Challenges and Opportunities of Data at the Hitachi Social Innovation Forum 2019

Artificial Intelligence and Pharma

AI Patent Policy – Calling all Life Sciences Practitioners

By: Anna Yuan and Karen G Potter